News

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV)…
Read More...

Nexus Pharmaceuticals announced the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals’ Arsenic Trioxide Injection is available as 10mg…
Read More...

Adynxx and twoXAR announced an agreement to develop an oral, non-hormonal drug therapy with the potential to address the underlying mechanisms of endometriosis and significantly improve…
Read More...

Five Prime Therapeutics announced it initiated patient dosing in a Phase 1 clinical trial of FPT155, a first-in-class CD80 fusion protein. The trial was initiated in Australia. “We…
Read More...

Lonza announced the appointment of Allen Burgenson, Global Subject Matter Expert for Endotoxin Detection at Lonza, as Chair of the Horseshoe Crab Advisory Panel of the Atlantic States…
Read More...

Grünenthal announced that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be…
Read More...

Dragonfly Therapeutics announced it entered into a new agreement with Celgene Corporation and its affiliates to discover, develop and commercialize innovative immunotherapies for…
Read More...

AbbVie announced new data for its pan-genotypic chronic hepatitis C virus (HCV) treatment, MAVYRET (glecaprevir/pibrentasvir), in treatment-naïve patients with compensated cirrhosis.…
Read More...

Catalent Pharma Solutions announced its plans to invest $2.5 million in a new, second clinical supply facility in Shanghai, China, due to open in early 2019. When completed, the…
Read More...

SGS announced that it has expanded elemental analysis testing capabilities at its Chennai, India laboratory. The site has invested in three inductively coupled plasma mass…
Read More...

Ferring Pharmaceuticals announced that it has signed an agreement to acquire from INVO Bioscience Inc. the exclusive U.S. commercialization rights for the INVOcell intravaginal culture…
Read More...

Enable Injections announced it has entered into development agreements with Apellis Pharmaceuticals, and most recently, UCB. Enable Injections currently has partnerships with five…
Read More...

Aimmune Therapeutics announced that Nestlé Health Science will make an additional equity investment in Aimmune of $98 million, increasing Nestlé Health Science’s ownership of Aimmune to…
Read More...

Pain Therapeutics announced that it has petitioned the Food & Drug Administration (FDA) regarding a Complete Response Letter (CRL) for REMOXY issued August 2018.  The FDA and the…
Read More...

Metrics Contract Services (Metrics), a division of Mayne Pharma Group Limited, announced successful qualification of two commercial bottling lines for serialization at its new US$80…
Read More...

BridgeBio Pharma LLC and Cincinnati Children's Hospital Medical Center announced that they are entering into a research collaboration to identify and develop genetic disease therapies.…
Read More...

Ziopharm Oncology announced a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate Ziopharm’s Ad-RTS-hIL-12 plus veledimex in combination with Regeneron’s PD-1…
Read More...

CRISPR Therapeutics and MaxCyte announced the expansion of their existing relationship by entering into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics…
Read More...

Genkyotex announced that its lead product candidate GKT831, a NOX1/4 inhibitor, met both the primary and secondary interim efficacy endpoints with high statistical significance after…
Read More...

Lonza announced that the recombinant Factor C (rFC) Assay has been used for endotoxin testing of Eli Lilly’s Emgality (galcanezumab), the first drug approved by the U.S. Food and Drug…
Read More...